Dieter Natlacen

More Than Share and Asset Deals: Innovative Transaction Structures for MedTech Companies

par Christopher Peine

Advising on Tropic Biosciences' US$105 million Series C financing

par plusieurs auteurs

Biopharma partnering update: Q4 2025

par plusieurs auteurs

Reform of the MDR and IVDR – A critical look at the Commission's proposal of 16 December 2025

par Dr. Wolfgang Rehmann

MedTech Regulation as a Strategic Lever

Advising on Infinitopes' expanded seed financing to US$35 million

par Ross McNaughton et Oli Denne

Oli Denne recognised in The Lawyer's Hot 100 2026

par Oli Denne et Shane Gleghorn

Research and innovation as a competitive advantage – Legal framework for Life Sciences made in Europe

par Irina Rebin

Life Sciences Made in Europe – The European Commission’s Life Sciences Strategy 2030

par Irina Rebin

Adoption of Commission Implementing Regulation (EU) 2025/2086: New Rules on the Joint Clinical Assessment of Medical Devices and In Vitro Diagnostic Medical Devices

par Irina Rebin et Daniel Dietrich